What Age to Get First Pap Smear With Family History of Ovarian
Cancer Screening Guidelines
Am Fam Medico. 2001 Mar 15;63(6):1101-1113.
Related Editorial
Article Sections
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Pare Cancer
- Testicular Cancer
- References
Numerous medical organizations have developed cancer screening guidelines. Faced with the wide, and sometimes conflicting, range of recommendations for cancer screening, family physicians must determine the near reasonable and up-to-appointment method of screening. Major medical organizations have generally accomplished consensus on screening guidelines for breast, cervical and colorectal cancer. For breast cancer screening in women ages 50 to seventy, clinical breast examination and mammography are generally recommended every one or two years, depending on the medical organisation. For cervical cancer screening, most organizations recommend a Papanicolaou test and pelvic examination at to the lowest degree every 3 years in patients betwixt 20 and 65 years of age. Almanac fecal occult claret testing forth with flexible sigmoidoscopy at five-year to 10-year intervals is the standard recommendation for colorectal cancer screening in patients older than 50 years. Screening for prostate cancer remains a matter of debate. Some organizations recommend digital rectal examination and a serum prostate-specific antigen test for men older than fifty years, while others do not. In the absence of compelling evidence to point a high risk of endometrial cancer, lung cancer, oral cancer and ovarian cancer, well-nigh no medical organizations have developed cancer screening guidelines for these types of cancer.
Several studies1 show that primary intendance physicians do not always comply with cancer screening guidelines. One reason is that recommendations for cancer detection and screening are often fragmented in the sense that they are developed past various medical organizations, which may make controlling more difficult as far every bit which recommendations to follow.
Table ane summarizes cancer screening recommendations from different medical organizations for low-risk patients. Table 2 describes what cancer screening procedures are currently covered past Medicare.
TABLE 1
Summary of Cancer Screening Recommendations for Low-Risk Patients
| Medical system | Screening recommendations |
|---|---|
| Breast cancer | |
| MAMMOGRAPHY | |
| AAFP | Every 1 to 2 years, ages l to 69; counsel women ages xl to 49 about potential risks and benefits of mammography and clinical breast examination. |
| ACOG | Every ane to 2 years starting at age 40, yearly after historic period fifty |
| ACS | Annually after age forty |
| AMA | Every 1 to 2 years in women ages 40 to 49; annually starting time at age fifty |
| CTFPHC | Every 1 to 2 years, ages fifty to 59 |
| NIH | Data currently available do not warrant a universal recommendation for mammography for women in their 40s; each woman should decide for herself whether to undergo mammography. |
| USPSTF | Every ane to 2 years, ages fifty to 69 |
| CLINICAL BREAST EXAMINATION | |
| AAFP | Every 1 to 2 years, ages 50 to 69; counsel women ages twoscore to 49 about potential risks and benefits of mammography and clinical chest exam. |
| ACOG | Yearly (or equally appropriate) general health evaluation that includes examination to detect signs of premalignant or malignant conditions |
| ACS | Every 3 years, ages 20 to 39; yearly after age forty; monthly chest self-examination offset at age 20 |
| AMA | Continuation of clinical breast examinations in asymptomatic women older than age twoscore |
| CTFPHC | Yearly, ages fifty to 69 |
| USPSTF | Insufficient prove to recommend for or against using clinical breast examination alone; optional every one to ii years, ages 50 to 69 |
| Cervical cancer | |
| AAFP | Pap test at least every 3 years to women who take ever had sexual intercourse and who have a cervix |
| ACOG | Almanac Pap test and pelvic examination first at age 18 or when sexually active; later 3 or more tests with normal results, Pap test may be performed less ofttimes on physician's advice. |
| ACS | Pap test annually starting at historic period eighteen or when sexually active; after 2 to three normal (negative) tests, keep at discretion of physician. |
| AGS | Pap test every iii years until historic period 70; in women of any age who have never had a Pap test, screening with at least 2 negative smears 1 year apart |
| AMA | Annual Pap exam and pelvic exam starting at age eighteen (or when sexually agile); after 3 or more than normal annual Pap tests, the Pap test may exist performed less oft at the md'southward discretion. |
| CTFPHC | Pap examination annually get-go at age 18 or following initiation of sexual activity; after 2 normal Pap results, perform Pap tests every three years to historic period 69. |
| USPSTF | Pap test at least every three years in women who have ever had sexual intercourse and who accept a cervix; discontinue regular testing after historic period 65 if Pap exam results have been consistently normal. |
| Colorectal cancer | |
| AAFP | No published standards or guidelines for low-risk patients |
| ACOG | Later age 50, annual FOBT (DRE should accompany pelvic exam); sigmoidoscopy every 3 to v years |
| ACS | After age 50, yearly FOBT plus flexible sigmoidoscopy and DRE every 5 years or colonoscopy and DRE every x years or double-contrast barium enema and DRE every 5 to 10 years |
| AMA | Annual FOBT beginning at historic period 50, and flexible sigmoidoscopy every iii to 5 years kickoff at age l |
| AGA | FOBT beginning at age 59 (frequency not specified); sigmoidoscopy every v years, double-dissimilarity barium enema every 5 to 10 years or colonoscopy every 10 years. |
| CTFPHC | Insufficient show to recommend using FOBT screening in the periodic health exam of individuals older than age twoscore; bereft evidence to recommend sigmoidoscopy in the periodic health examination; insufficient evidence to recommend screening with colonoscopy in the general population |
| USPSTF | Afterward age 50, yearly FOBT and/or sigmoidoscopy (unspecified frequency for sigmoidoscopy) |
| Prostate cancer | |
| AAFP | No published standards or guidelines for low-risk patients |
| ACP-ASIM | Physicians should depict potential benefits and known harms of screening, diagnosis and treatment; listen to the patient'south concerns, then individualize the decision to screen. |
| ACS and AUA | Offer annual DRE and PSA screening, start at age fifty, to men who have at least a 10-year life expectancy and to younger men at high adventure. |
| AMA | Provide data regarding the risks and potential benefits of prostate screening. |
| CTFPHC and USPSTF | DRE and PSA tests are not recommended for the general population. |
| Skin cancer | |
| ACS | Cancer-related checkup, including pare examination every 3 years between ages 20 and forty, and every year for anyone historic period 40 and older |
| AMA | Patients should talk to their physicians about the frequency of screening for skin cancer (those at modestly increased risk should see a principal intendance physician annually); skin self-examination should be performed monthly. |
| CTFPHC | Insufficient bear witness to recommend for or against total-body skin examination or cocky-examination; counsel on avoiding sunday exposure and wearing protective clothing. |
| USPSTF | Insufficient evidence to recommend for or against routine screening for skin cancer by primary care clinicians or counseling patients to perform periodic pare examination. |
| Testicular cancer | |
| ACS | Examine testicles equally part of a cancer-related checkup. |
| CTFPHC | Bereft evidence to recommend routine examination of testes by medico or by patient self-exam |
| USPSTF | Insufficient evidence to recommend for or against routine screening of asymptomatic men in the general population by physician exam or patient self-examination |
Tabular array 2
Medicare Coverage for Cancer Screening Procedures
| Type of cancer | Description of Medicare coverage |
|---|---|
| Breast | Annual screening mammography for women older than historic period xl |
| Cervix | Pap testing and pelvic examination at three-year intervals. Yearly screening is immune for women who are at a high gamble of cervical or vaginal cancer or who have had an abnormal Pap smear in the preceding three years. |
| Colorectal | For individuals older than l years, screening fecal occult blood testing is reimbursed past Medicare one time per year and flexible sigmoidoscopy is reimbursed once every four years or in one case every two years if the patient is at high risk. Colonoscopy is reimbursed every 2 years if the patient is at high risk for colon cancer (no age limit). Barium enema is reimbursed equally a substitute for sigmoidoscopy or colonoscopy if the primary care physician deems it appropriate. |
| Prostate | Almanac digital rectal examination and prostate-specific antigen test in men older than l years |
Recommendations adult by the Canadian Job Force on Preventive Health Care (CTFPHC) and by the U.South. Preventive Services Task Force (USPSTF) are based on an explicit methodology for evaluating and weighing the force of the evidence. With the other medical organizations mentioned in this commodity, cancer screening guidelines take generally been formulated from a combination of a literature review and expert opinion.
Breast Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Testicular Cancer
- References
An estimated 182,800 new cases of breast cancer were diagosed in American women in 2000. Chest cancer ranks second as a crusade of cancer-related deaths in women, with 41,200 deaths (forty,800 in women and 400 in men) were predicted to occur in 2000.2
Numerous clinical trials have evaluated the benefits of the three about ordinarily recommended screening tests: mammography, breast self-examination and clinical breast examination.
SCREENING RECOMMENDATIONS FOR Low-Run a risk PATIENTS
CTFPHC recommends screening by mammography every twelvemonth in women ages fifty to 69. Evidence suggests that such screening is associated with a pregnant decrease in mortality in this historic period group.3 USPSTF recommends mammography every one to 2 years, with or without clinical breast examination, in women ages fifty to 69.4
The American College of Radiology supports almanac mammography and clinical breast examinations starting at age forty.5
The American Higher of Obstetricians and Gynecologists (ACOG) recommends annual clinical chest examinations accompanied by mammography every one to two years in women from twoscore to fifty years of age and annually subsequently historic period 50.6 The American Medical Clan (AMA) recommends mammograms and clinical chest examinations annually in women fifty years and older and mammography and clinical breast examinations every i to 2 years in women betwixt 40 and 49 years of age.7
The American Cancer Lodge (ACS) recommends mammography annually subsequently historic period forty; clinical breast examination is recommended every three years in women between xx and 39 years of age and annually later age 40.two The American Academy of Family Physicians (AAFP) recommends mammography and clinical chest examination every one to two years in women ages 50 to 69.eight
SCREENING RECOMMENDATIONS FOR HIGH-Adventure PATIENTS
USPSTF does not specifically recommend mammography or clinical chest examination in women younger than 50 years who are at increased run a risk of breast cancer, but leaves information technology up to the discretion of the patient and dr.. However, such screening may exist recommended for a patient at high risk of breast cancer based on the patient'south and doctor's preferences and the college frequency of a positive predictive value of screening in the high-risk group.4
Cervical Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Pare Cancer
- Testicular Cancer
- References
An estimated 12,800 cases of invasive cervical cancer were diagnosed in 2000 and an estimated four,600 women died of the disease.2 Mortality and incidence rates have declined sharply over the past several decades.2
SCREENING RECOMMENDATIONS FOR ALL PATIENTS
There is consensus amid medical organizations for regular cervical cancer screening with Papanicolaou (Pap) tests in women who accept e'er been sexually agile. The recommendations differ in the frequency of Pap tests and the historic period at which regular Pap tests should begin and stop.
ACOG, ACS, AMA and CTFPHC recommend annual screening with a Pap test and pelvic examination in all women who are or who have been sexually agile or who are 18 years and older.ii,3,half dozen,7 The frequency of Pap tests may exist decreased at the discretion of the dr. after 2 or iii consecutive normal tests. CTFPHC recommends Pap tests every three years until the age of 69. The frequency may be increased if whatsoever take a chance factors are present, including historic period eighteen or younger at the time of first sexual intercourse, having numerous sexual partners, smoking or having a depression socioeconomic condition.iii
USPSTF and AAFP recommend Pap tests at least every three years for all women who have ever had sexual intercourse and who have a neck.4,8 A Pap test every one or ii years equally compared with every three years has been institute to better the screening effectiveness past less than v percent.9 USPSTF recommends discontinuing regular Pap testing after age 65 in women who take had consistently normal results on previous tests.4
The American Elderliness Society (AGS) recommends Pap tests every three years until age 70 and suggests that cervical cancer screening, with two negative tests ane twelvemonth apart, be performed in a woman of whatever age who has never had a Pap test.x It has been establish that Pap testing may not be useful in elderly women who take consistently normal results. Modeling data advise that continued testing of previously screened women reduces the gamble of cervical cancer mortality by but 0.xviii percent at age 65 and by 0.06 percent at historic period 74.ix
For women who have had a hysterectomy, AGS recommends screening only if the cervical cuff is still nowadays.10 Similarly, USPSTF recommendations land that Pap testing is not required in women who take undergone a hysterectomy in which the cervix was removed, unless the surgery was performed because of cervical cancer or its precursors.4
Colorectal Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Testicular Cancer
- References
Colorectal cancer is the third near common cancer. Approximately 130,200 new cases (93,800 of the colon and 36,400 of the rectum) were diagnosed in 2000, and this illness accounted for an estimated 56,300 deaths (47,700 from colon cancer and viii,600 from rectal cancer) in 2000. Mortality rates for colorectal cancer accept declined in men and women during the past twenty years.2
High-risk patients include patients younger than threescore years with a history of hereditary nonpolyposis colorectal cancer, familial polyposis, ulcerative colitis, high-gamble adenomatous polyps or previous colorectal cancer.
SCREENING RECOMMENDATIONS FOR LOW-RISK PATIENTS
USPSTF recommends fecal occult blood testing (FOBT) yearly outset at historic period 50. Sigmoidoscopic screening is also suggested as an alternative to FOBT but with no recommended frequency. USPSTF concludes that at that place is insufficient evidence to back up screening with the digital rectal examination (DRE), barium enema or colonoscopy.four
ACOG recommends FOBT annually and sigmoidoscopy every three to five years afterward the age of 50. DRE should exist performed at the time of pelvic examination.6
AMA supports almanac FOBT beginning at age 50, and flexible sigmoidoscopy every iii to five years showtime at age 50. Colonoscopy and/or double-contrast barium enema are advisable alternatives to sigmoidoscopy.11
ACS recommends one of iii options for average-run a risk persons later on historic period 50: yearly FOBT plus flexible sigmoidoscopy every 5 years, colonoscopy every x years or double-dissimilarity barium enema every five to x years.8,12 For all the above screening options, DRE should be performed simultaneously.ii
The American Gastroenterological Association (AGA) recommends FOBT kickoff at age 50 (no frequency specified) for screening for colorectal cancer and adenomatous polyps in all men and women without risk factors. In addition, screening sigmoidoscopy should exist performed every v years, a double-contrast barium enema every five to x years or colonoscopy every 10 years.13
AAFP guidelines are like to the AGA guidelines. CTFPHC states that at that place is bereft evidence to recommend use of FOBT screening, sigmoidoscopy or colonoscopy in the full general population older than age 40.3
SCREENING RECOMMENDATIONS FOR HIGH-RISK PATIENTS
USPSTF recommends regular endoscopic screening in patients with a family history of hereditary syndromes associated with a high take chances of colon cancer (i.e., familial polyposis and hereditary nonpolyposis colorectal cancer) and in patients with ulcerative colitis, high-gamble adenomatous polyps or colon cancer. Referral to a subspecialist is advisable in such cases.4
ACS recommends the same screening options for depression-take a chance and loftier-risk patients (i.eastward., a history of cancer or polyps before age 60 in a starting time-degree relative or in two first-degree relatives of any age, or a personal history of colorectal cancer, adenomatous polyps or chronic inflammatory bowel illness) but recommends that screening begin at an before age and/or be performed more often in patients at high risk of colorectal cancer.8
AAFP guidelines recommend that adults 40 years and older with a family history of early colorectal cancer undergo FOBT annually and sigmoidoscopy, barium enema or colonoscopy (the frequency of these procedures is not specified).8
AGA recommends screening starting at age forty for persons with kickoff-degree relatives with colon cancer (Table 3).13
Tabular array 3
American Gastroenterological Association Recommendations for Colorectal Cancer Screening in Patients at Increased Risk
| Patients with a close relative who has had colorectal cancer or an adenomatous polyp | |
| Recommendation: | |
| Patients with a sibling, parent or kid who has had colorectal cancer or an adenomatous polyp should be offered the same options every bit boilerplate-risk persons but outset at historic period forty instead of age 50. If colorectal cancer was diagnosed in the close relative before age 55 or if an adenomatous polyp was diagnosed in the close relative before age threescore, special efforts should exist fabricated to ensure that screening takes place. | |
| Patients with a family history of familial adenomatous polyposis | |
| Recommendation: | |
| Patients with a family history of familial adenomatous polyposis should receive genetic counseling and consider genetic testing to see if they are gene carriers. A negative genetic test result rules out familial adenomatous polyposis but if an affected family member has an identified mutation. Patients who are gene carriers or in whom the findings are indeterminate should be offered flexible sigmoidoscopy every year, beginning at puberty, to see if they are expressing the factor. If polyposis is present, they should begin to consider when colectomy should be performed. | |
| Patients with a family history of hereditary nonpolyposis colorectal cancer | |
| Recommendation: | |
| Patients with a family unit history of colorectal cancer in multiple close relatives and across generations, especially if cancer occurred at a young historic period, should receive genetic counseling and consider genetic testing for hereditary nonpolyposis colorectal cancer. They should be offered an test of the entire colon every one to two years starting between the ages of 20 and 30 and every year after historic period 40. | |
| Patients with a history of adenomatous polyps | |
| Recommendation: | |
| Patients in whom big (more than than one cm in diameter) or multiple adenomatous polyps are found and removed at colonoscopy should have an exam of the colon 3 years after the initial test. The interval for subsequent examinations depends on the type of polyps that were detected. If the first follow-up is normal or only a single, small, tubular adenoma is plant, the side by side examination can be in five years. In special circumstances (such every bit polyps with invasive cancer, big sessile adenomas or numerous adenomas), a shorter interval may be necessary, according to the judgment of the clinician and the wishes of the patient. | |
| Patients with a history of colorectal cancer | |
| Recommendation: | |
| Patients with colorectal cancer that has been resected with curative intent (but who did not undergo consummate acceptable colonoscopic examination preoperatively) should undergo a complete test of the colon within one yr after resection. If this test reveals normal findings or the consummate preoperative examination was normal, subsequent test should be offered afterward iii years; if the findings of this exam are normal, colonoscopy should then exist performed every five years. | |
| Patients with inflammatory bowel disease | |
| Recommendation: | |
| In patients with longstanding, extensive inflammatory bowel affliction, surveillance colonoscopy, looking for dysplasia as a marker or colorectal cancer risk, should be considered forth with the extent and duration of the disease every bit a guide to when or whether colectomy should be a consideration. | |
Endometrial Cancer
- Abstruse
- Chest Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Testicular Cancer
- References
An estimated 36,100 cases of cancer of the uterine corpus, usually of the endometrium, were expected to be diagnosed in 2000.2 Incidence rates are higher among white women (22.four per 100,000) than among blackness women (15.3 per 100,000). Approximately six,500 deaths as a result of endometrial cancer were predicted in 2000.ii The incidence of endometrial cancer increases with age, peaking at 100.7 cases per 100,000 women between the ages of 70 and 75.14
SCREENING RECOMMENDATIONS FOR Low-RISK PATIENTS
ACOG, ACS, CTFPHC and USPSTF have not issued any recommendations for endometrial cancer screening, such as by biopsy or ultrasound, in women at depression take chances of this disease. ACOG states that screening for endometrial cancer is neither cost-effective nor warranted.6
SCREENING RECOMMENDATIONS FOR HIGH-RISK PATIENTS
ACS recommends endometrial biopsy starting at menopause then periodically at the discretion of the physician in women at loftier take chances of endometrial cancer.2 On the basis of skilful opinion only, a task strength organized by the National Institutes of Health (NIH) and the National Human Genome Inquiry Institute recommends screening for endometrial cancer in women with the hereditary nonpolyposis colorectal cancer.15 ACOG recommends that screening for endometrial cancer in women who are receiving tamoxifen (Nolvadex) exist left to the discretion of the physician.16
Lung Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Testicular Cancer
- References
Lung cancer is a leading cause of decease in men and women, accounting for an estimated 156,900 deaths in 2000, which translates to 28 percentage of all cancer-related deaths.two The five-yr survival rate is estimated to be less than 13 percent.four
SCREENING RECOMMENDATIONS FOR LOW-RISK PATIENTS
There is no evidence that screening for lung cancer is constructive. Cytologic examination of the sputum has non proven useful.3 Consequently, USPSTF does not recommend screening with breast radiographs or sputum cytology.4 Instead, USPSTF advises physicians to counsel against tobacco employ. In general, medical organizations have not developed any official recommendations for lung cancer screening. While a Japanese study17 suggests that mass screening with screw computed tomography may exist useful, further research is needed before such a recommendation can exist made.
SCREENING RECOMMENDATION FOR Loftier-RISK PATIENTS
According to CTFPHC and USPSTF, the evidence is strong that periodic screening with breast radiographs in high-risk patients does not reduce mortality from lung cancer. Radiography and sputum cytomorphologic test lack sufficient accurateness to be used in routine screening of patients with a history of smoking.3,4
Oral Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Pare Cancer
- Testicular Cancer
- References
Oral cancer accounts for three percentage of cancers in men and 2 percent of cancers in women.eighteen Mucosal erythroplasia, not leukoplakia, is the earliest sign of oral cancer.19
SCREENING RECOMMENDATIONS FOR Depression-RISK PATIENTS
The ii near common methods of screening for oral cancer are visual inspection and cytology, neither of which has been shown to reduce mortality from this disease.19 Therefore, major groups such as USPSTF and CTF-PHC country that, although screening can atomic number 82 to early on detection, there is insufficient evidence to recommend for or against routine screening for oral cancer.three,4 Both groups advocate educational programs directed toward reducing the utilise of tobacco and alcohol.
ACS has no official guidelines for oral cancer detection; all the same, it encourages primary care physicians to perform an exam of the whole mouth every bit part of a routine cancer-related checkup.8
SCREENING RECOMMENDATIONS FOR High-RISK PATIENTS
USPSTF recommends a regular dental examination in patients at high chance of oral cancer.four CTFPHC suggests annual examinations by a physician or a dentist to screen for oral cancer in patients older than 60 years with risk factors such as smoking and heavy drinking.three These recommendations are supported by big, strange studies of oral cancer screening, which prove that primary care physicians can discover premalignant lesions and early cancer in high-run a risk patients.20,21
Ovarian Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Testicular Cancer
- References
Ovarian cancer is the 2d most common gynecologic cancer, with 23,100 new cases and 14,000 deaths estimated to have occurred in 2000.2 A woman has a one-in-70 gamble of ovarian cancer in her lifetime. The incidence of ovarian cancer increases with age, from 1.4 cases per 100,000 in women younger than age twoscore to 45.0 cases per 100,000 in women older than sixty years.22 Ovarian cancer is the most lethal of all the gynecologic cancers, killing more than women each year than cervical and endometrial cancers combined.
SCREENING RECOMMENDATIONS FOR LOW-Take chances PATIENTS
The effectiveness of routine screening of asymptomatic women using pelvic exam, abdominal or vaginal ultrasound or serum carcinoembryonic antigen (CEA-125) has non been established. ACOG, the American College of Physicians-American Guild of Internal Medicine (ACP-ASIM), CTFPHC and USPSTF do not recommend routine screening for ovarian cancer.3,4,23,24 ACS recommends annual pelvic examinations starting at age 18 or when the adult female becomes sexually agile.2
SCREENING RECOMMENDATIONS FOR HIGH-Gamble PATIENTS
ACS states that women with a loftier risk of epithelial ovarian cancer, such as those with a very strong family history of the disease, may be screened with transvaginal ultrasound and CEA-125.eight CTFPHC indicates that evidence is insufficient to recommend for or against ovarian cancer screening in women who have more than ane first-degree relative with the illness.three
Merely 5 to x percent of patients with ovarian cancer accept a significant family history.22 However, three familial syndromes have been identified: site-specific ovarian cancer, familial breast-ovarian cancer syndrome and cancer familial syndrome (Lynch type Two).
In 1980, a tumor suppression gene (BRCA 1) was discovered on chromosome 17.24 The BRCA one mutation is associated with site-specific ovarian cancer and familial breast-ovarian cancer syndromes. These syndromes are transmitted in an autosomal dominant fashion with variable penetrance. Women with sure mutations in BRCA one take an increased adventure of ovarian cancer and breast cancer. The cumulative risk of ovarian cancer in women with BRCA 1 has been estimated to be 56 percent past historic period 70.25 A task force organized by the NIH and the National Human Genome Enquiry Institute recommends ovarian cancer screening by means of annual or semiannual transvaginal ultrasound and serum CEA-125 levels beginning at ages 25 to 35 in BRCA ane mutation carriers. The chore forcefulness did not result recommendations for or confronting elective oophorectomy in these patients.26
Prostate Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Pare Cancer
- Testicular Cancer
- References
Although incidence rates of prostate cancer are declining, estimates are that prostate cancer was diagnosed in 180,400 men in the The states during 2000. Approximately 31,900 men died of the disease, making it the 2d leading cause of cancer-related deaths in men.two The incidence of prostate cancer rises rapidly in each decade of life after the historic period of 50. In whites, the age-adjusted incidence is 108.3 cases per 100,000; in blacks, it is 142.0 per 100,000. Prostate cancer occurs more than frequently among men with a family history of prostate cancer.27
For many years, DRE has been one of the major screening methods for the detection of prostate cancer, although its truthful value equally a screening tool has never been proven conclusively. The majority of studies on the use of DRE for prostate cancer screening accept been observational and have yielded varying measures of sensitivity and survival. None accept shown that regular DRE screening reduces mortality from prostate cancer.28,29
Currently, use of the serum prostate-specific antigen (PSA) test as a screening tool for prostate cancer is controversial. Ane problem is that the PSA examination is prone to high rates of false-positive results, ranging from 67 to 93 percent, which leads to more invasive diagnostic procedures than are necessary.3 Data as well suggest that PSA screening detects what may exist indolent, nonaggressive prostate cancer. The treatment of such a cancer with radiation or radical prostatectomy may effect in significant and perhaps unnecessary morbidity.xxx On the other hand, the potential value of PSA testing has been discussed in several manufactures.31–33
The National Cancer Institute (NCI) and the U.S. Public Health Service are conducting a long-term multicenter cancer screening study, chosen the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial (PLCO), which includes a report of the bear upon of PSA screening on survival from prostate cancer. In addition, large prospective randomized studies on prostate cancer screening are underway in Canada and Europe. Hopefully, these studies volition settle the controversy surrounding PSA testing.
SCREENING RECOMMENDATIONS FOR LOW-RISK PATIENTS
Several medical organizations and government agencies have issued guidelines for prostate cancer screening that reflect the current controversy about the value of PSA testing. In that location is no consensus for using it to screen depression-run a risk patients. Citing insufficient evidence in support of DRE and PSA screening, CTFPHC and USPSTF practice not recommend routine DRE or PSA screening for asymptomatic men.3,iv ACP-ASIM advises counseling patients nigh the potential benefits and uncertainties associated with prostate cancer screening.23
AAFP has not adult specific standards or guidelines for prostate cancer screening.
ACS and the American Urological Association (AUA) recommend offering annual DRE and PSA screening, first at historic period l in men who have at least a ten-twelvemonth life expectancy and beginning at a younger age in men at loftier risk.two,33
The AMA recommends that patients discuss their medical history and risk factors for prostate cancer with their physicians. On the ground of this information, the patient and doc can make up one's mind when screening tests for prostate cancer should be performed.seven
SCREENING RECOMMENDATIONS FOR Loftier-RISK PATIENTS
ACS and AUA recommend annual testing of high-risk patients beginning at age 45.8,34 Loftier-gamble patients include African-Americans and patients who have ii or more than first-degree relatives with prostate cancer. Guidelines published by the other groups mentioned above do non specify routine DRE or PSA in high-risk patients. They recommend that the decision most prostate cancer screening be fabricated on an individual footing after consultation between the physician and the patient.2,33
Pare Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Peel Cancer
- Testicular Cancer
- References
Approximately 1.three 1000000 cases of highly curable basal or squamous cell cancer are diagnosed each year.2 In addition, approximately 47,700 cases of melanoma were diagnosed in 2000. Since the early 1970s, the incidence rate of melanoma has increased significantly—an boilerplate of four percent per yr. An estimated ix,600 persons died of peel cancer in 2000, with 7,700 dying of melanoma and 1,900 dying of other skin cancers.2 Several studies accept shown that patients who have complete peel examinations are half dozen.4 times more likely to have a melanoma detected as compared with patients who accept partial skin examinations.35
SCREENING RECOMMENDATIONS FOR Low-RISK PATIENTS
CTFPHC and USPSTF hold that at that place is insufficient evidence to decide whether a subtract in mortality occurs with routine exam of the skin in low-run a risk patients by chief care physicians.three,iv The same is true for cocky-examination. CTFPHC advises physicians to counsel patients about reducing lord's day exposure by using sun screen and wearing protective vesture.3
ACS recommends a cancer-related checkup, including skin test, every three years in patients between 20 and 40 years of age and yearly in patients older than xl years.two
AMA advises patients to hash out the frequency of screening for skin cancer with their medico and perform skin cocky-examinations monthly.7 Annual skin examinations are recommended in patients at moderately increased risk.7
The American Academy of Dermatology recommends that individuals prefer a comprehensive sun protection plan and perform regular self-examinations of the skin. Whatsoever unusual peel changes should exist evaluated.35
SCREENING RECOMMENDATION FOR Loftier-Hazard PATIENTS
CTFPHC and USPSTF recommend that patients at loftier risk of melanoma, such as those with familial melanoma syndrome or a get-go-degree relative with melanoma, be referred to a dermatologist for monitoring and screening examinations.iii,4 For patients with a family unit history of melanoma, regular total pare examination should be considered.3,iv
Testicular Cancer
- Abstract
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Lung Cancer
- Oral Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Testicular Cancer
- References
The Surveillance Research Program of the ACS Department of Epidemiology and Surveillance Research estimates that 6,900 cases of testicular cancer were diagnosed in 2000. An estimated 300 men died of this affliction.18 Testicular cancer represents one.one percent of cancers among men. The lifetime probability of developing testicular cancer is 0.thirty percent and the lifetime probability of dying of this disease is 0.03 percent. It is the about common cancer in males ages 15 to 34, and the incidence has been increasing in this age grouping.3
SCREENING RECOMMENDATIONS FOR Depression-Take a chance PATIENTS
CTFPHC and USPSTF state that there is bereft bear witness to indicate that screening (either with testicular self-examination or by a primary care doc) would consequence in a decrease in the mortality rate from this cancer.iii,four ACS advises a testicular examination as part of a routine cancer-related checkup.8
SCREENING RECOMMENDATIONS FOR Loftier-Risk PATIENTS
ACS and CTFPHC recommend that individuals at increased risk of testicular cancer, such equally those with testicular atrophy, cryptic genitalia or cryptorchidism, be informed of their increased gamble and counseled regarding screening options.ii,3 While ACS suggests monthly examinations in high-risk patients, CTFPHC indicates that the optimal frequency of such examinations has non been adamant and should exist left to clinical discretion.2,three
AAFP formerly recommended a testicular examination for all males in the xiii-year-onetime to 39-year-old age group with a history of cryptorchidism, orchiopexy and/or testicular atrophy. Currently, AAFP provides no recommendations for testicular cancer screening in the general population.8
To meet the total commodity, log in or buy admission.
REFERENCES
show all references
1. Young JM, Ward JE. Strategies to improve cancer screening in full general practise: are guidelines the answer? Fam Pract. 1999;16:66–seventy. ...
2. American Cancer Order. Prevention and early detection. Retrieved September 21, 2000, from the Www: http://world wide web.cancer.org/statistics/cff2000/selected_toc.html.
iii. Canadian Chore Force on Preventive Health Care. CTFPHC Systematic reviews and recommendations. Retrieved March 13, 2000, from the Globe Wide Web: http://www.ctfphc.org.
4. The states Preventive Services Job Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996. Retrieved September 19, 2000, from the Www: http://text.nlm.nih.gov.
5. American College of Radiology. Breast intendance guidelines. 2nd ed, 1996. Retrieved March 12, 2000, from the Earth Wide Web: http://www.acr.org/f-search.html.
6. American College of Obstetricians and Gynecologists. Routine cancer screening. ACOG opinion, no. 185. Washington, D.C., 1997.
7. American Medical Association. Cancer screening guidelines [perform a search for specific types of cancer]. Retrieved September twenty, 2000, from the Earth Broad Spider web: http://www.ama-assn.org.
8. American Academy of Family Physicians. Summary of policy recommendations for periodic wellness examination. Retrieved September xix, 2000, from the World Wide Web: https://world wide web.aafp.org/test.
9. Eddy DM. Screening for cervical cancer. Ann Intern Med. 1990;113:214–26.
10. American Geriatric Society. Clinical practice statement: screening for cervical carcinoma in elderly women. Retrieved September 21, 2000, from the World wide web :http://www.americangeriatrics.org/positionpapers/alphabetize.html.
11. American Medical Clan. Study 7 of the Quango on Scientific Affairs (I-98). Recommendations for colorectal cancer screening and surveillance in people at average and at increased adventure. Retrieved September 21, 2000, from the Www: http://www.amaassn.org/ama/pub/article/2036-2049.html.
12. Smith RA, Mettlin CJ, Johnston-Davis KJ, Eyre D. American Cancer Society guidelines for early detection of cancer. CA J Clin. 2000;fifty:34–49.
13. American Gastroenterological Association. New national colorectal cancer practice guidelines recommend life-saving tests. Retrieved September 21, 2000, from the World Wide Spider web: http://www.gastro.org/phys-sci/colcancer/index.html.
14. Schottenfeld D. Epidemiology of endometrial neoplasia. J Cell Biochem Suppl. 1995;23:151–nine.
15. Burke Due west, Petersen Yard, Lynch P, Botkin J, Daly M, Garber J, et al. for Cancer Genetics Studies Consortium. Recommendations for follow-up intendance of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. JAMA. 1997;277:915–9.
xvi. American College of Obstetricians and Gynecologists.. ACOG committee opinion no. 169, February 1996. Tamoxifen and endometrial cancer. Int J Gynaecol Obstet. 1996;53:197–9.
17. Sone S, Takashima Due south, Li F, Yang Z, Honda T, Maruyama Y, et al. Mass screening of lung cancer with mobile screw computed tomography scanner. Lancet. 1998;351:1242–5.
18. Greenlee RT, Murray T, Bolden Due south, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;l:seven–33.
19. Mashberg A, Samit AM. Early detection, diagnosis, and management of oral and oropharyngeal cancer. CA Cancer J Clin. 1989;39:67–88.
20. Mehta FS, Gupta PC, Bhonsle RB. Detection of oral cancer using basic wellness workers in an area of high oral cancer incidence in India. Cancer Notice Prev. 1986;ix:219–25.
21. Warnakulasuriya KA, Nanayakkara BG. Reproducability of an oral cancer and pre-cancer detection program using primary care health model in Sri Lanka. Cancer Discover Prev. 1991;xv:331–4.
22. American College of Obstetricians and Gynecologists.. Ovarian cancer. ACOG educational bulletin, no. 25. Obstet Gynecol. 1998;72(two).
23. American College of Physicians–American Society of Internal Medcine. Clinical guidelines: screening for prostate cancer. Retrieved September 20, 2000, from the Globe Broad Web: http://www.acponline.org/journals/annals/15Mar97/ppscreen.htm.
24. Rosenthal TC, Puck SM. Screening for genetic chance of breast cancer. Am Fam Doc. 1999;59:99–104.
25. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams 1000, et al. The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 amid Ashkenazi Jews. N Engl J Med. 1997;336:1401–8.
26. Kerlikowske K, Brownish JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992;80:700–7.
27. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and risk of prostate cancer. Prostate. 1990;17:337–47.
28. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam department of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 1998;xc:1817–23.
29. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1997;1:i,ane–96.
xxx. Lefevre ML. Prostate cancer screening: more harm than good? Am Fam Doc. 1998;58:432–8.
31. Labrie F, Candas B, Dupont A, Cusan 50, Gomez JL, Suburu RE, et al. Screening decreases in prostate cancer decease: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial. Prostate. 1999;38:83–91.
32. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance serial: interpreting trends in prostate cancer—office I: evidence of the furnishings of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–24.
33. Ruffin MT. Screening for prostate cancer. J Fam Pract. 1999;48:581–2.
34. American Urological Association. Early on detection of prostate cancer. Retrieved September 21, 2000, from the World wide web: http://www.auanet.org/pub_pat/policies/uroservices.html.
35. Rigel DS, Friedman RJ, Kopf AW, Weltman R, Prioleau PG, Safai B, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol. 1986;14(v pt one):857–60.
Copyright © 2001 by the American Academy of Family Physicians.
This content is endemic by the AAFP. A person viewing information technology online may make i printout of the fabric and may use that printout but for his or her personal, non-commercial reference. This textile may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or subsequently invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.
MOST Recent Outcome
Feb 2022
Access the latest effect of American Family Md
Read the Issue
Email Alerts
Don't miss a single issue. Sign upward for the free AFP email tabular array of contents.
Sign Up Now
Source: https://www.aafp.org/afp/2001/0315/p1101.html
0 Response to "What Age to Get First Pap Smear With Family History of Ovarian"
Post a Comment